Drug Trial Radar · NCT06393452
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Jun 5, 2024
Primary completion
Jul 16, 2025
Study completion Oct 1, 2025
Sponsor
- Lead sponsor
- Pelage Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK. Part 1 of the trial is the randomized controlled portion that will focus on safety and PK following 28 days of blinded treatment administration with either PP405 or vehicle control. Part 2 of the trial is an open-label extension that will validate the results of Part 1 with 3 months of treatment administration.
Conditions
- Androgenetic Alopecia
Interventions
PP405 0.05% Topical GelDrug
Medicated topical gel containing PP405 0.05%, applied once daily to the scalp
Topical Vehicle GelDrug
Vehicle = placebo topical gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Adverse EventsTime frame: Baseline to Day 84 of the randomized portion of the study
- Percentage of Subjects With Adverse EventsTime frame: Baseline to Day 84 of the open label extension portion of the study
- Change in Local Dermal Tolerability as Assessed by Subject and InvestigatorTime frame: Post-dose at day 28 of the randomized portion of the study
- Change in Local Dermal Tolerability as Assessed by Subject and InvestigatorTime frame: Post-dose at day 84 of the open label extension portion of the study
- Change From Baseline in Blood PressureTime frame: Baseline to Day 84 of the randomized portion of the study
- Change From Baseline in Pulse RateTime frame: Baseline to Day 84 of the randomized portion of the study
- Change From Baseline in TemperatureTime frame: Baseline to Day 84 of the randomized portion of the study
- Change From Baseline in Respiratory RateTime frame: Baseline to Day 84 of the randomized portion of the study
- Change From Baseline in WeightTime frame: Baseline to Day 84 of the randomized portion of the study
- Change From Baseline in Blood PressureTime frame: Baseline to Day 84 of the open label extension portion of the study
- Change From Baseline in Pulse RateTime frame: Baseline to Day 84 of the open label extension portion of the study
- Change From Baseline in TemperatureTime frame: Baseline to Day 84 of the open label extension portion of the study
- Change From Baseline in Respiratory RateTime frame: Baseline to Day 84 of the open label extension portion of the study
- Change From Baseline in WeightTime frame: Baseline to Day 84 of the open label extension portion of the study
- Change From Baseline in Mean Electrocardiogram Heart RateTime frame: Baseline to day 28 of the randomized portion of the study
- Change From Baseline in Electrocardiogram (ECG) ResultsTime frame: Baseline to day 28 of the randomized portion of the study
- Change From Baseline in Mean Electrocardiogram Heart RateTime frame: Baseline to day 84 of the open label extension portion of the study
- Change From Baseline in Electrocardiograms (ECGs)Time frame: Baseline to day 84 of the open label extension portion of the study
- Abnormal Laboratory ValuesTime frame: Day 28 post baseline in the randomized portion of the study
- Abnormal Laboratory ValuesTime frame: Day 84 post baseline in the open label extension portion of the study
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
California Dermatology & Clinical Research Institute
Encinitas, California
Clinical Trials Research Institute
Thousand Oaks, California
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Minnesota Clinical Study Center
New Brighton, Minnesota
DermResearch
Austin, Texas
Stride Clinical Research LLC
Sugar Land, Texas
Jordan Valley Dermatology Center
South Jordan, Utah
Virginia Clinical Research, Inc.
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.